Prevalence and Risk Factors of Myocardial Remodeling in Hemodialysis Patients

REFERENCES

• Morton CC. U.S. dialysis survival strategy. Ann Intern Med. 1998;128:514–516.
   PubMedGoogle Scholar
• Raine AEG, Margreiter R, Brunner FP. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant. 1992;7(Suppl. 2):7–35.
   PubMed Web of Science ®Google Scholar
• Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697–701.
   PubMed Web of Science ®Google Scholar
• Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol. 2001;12:1079–1084.
   PubMed Web of Science ®Google Scholar
• Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36:286–290.
   PubMed Web of Science ®Google Scholar
• Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med. 1992;117:826–831.
   Google Scholar
• Levy D, Garrison RJ, Savadge DD, Kannel WB, Castelli WP. Prognostic implication of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;332:1561–1566.
   Web of Science ®Google Scholar
• Bolognese L, Dellavessa P, Rossi L, Sarasso G, Bongo AS, Scianaro MC. Prognostic value of left ventricular mass in uncomplicated acute myocardial infarction and one-vesel coronary artery disease. Am J Cardiol. 1994;73:1–5.
   PubMed Web of Science ®Google Scholar
• London GM, Fabiani F, Marchais SJ, de Vernejoul MC, Guerin AP, Safar ME, Metivier F, Llach F. Uremic cardiomyopathy: An inadequate left ventricular hypertrophy. Kidney Int. 1987;31:973–980.
   PubMed Web of Science ®Google Scholar
• Foley R N, Parfrey PS, Harnett J D, Kent GM, Murray DC, Barré PE. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol. 1995;5:2024–2031.
   PubMedGoogle Scholar
• Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertentoin. Ann Intern Med. 1991;114:342–352.
   Google Scholar
• Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol. 1995;25:879–884.
   PubMed Web of Science ®Google Scholar
• Shigematsu Y. Clinical evidence for association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension. J Hypertens. 1995;13:155–160.
   PubMedGoogle Scholar
• Verdecchia P, Giuseppe S, Borgioni C, Ciucci A, Battistelli M, Bartoccini C, Santucci A, Santucci C, Reboldi G, Porcellati C. Adverse prognostic significance of concentric remodelling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol. 1995;25(4):871–878.
   PubMed Web of Science ®Google Scholar
• Parfrey PS. Cardiac disease in dialysis patients: Diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant. 2000;15(Suppl. 5):58–68.
   PubMed Web of Science ®Google Scholar
• Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertention. J Am Coll Cardiol. 1992;19:1550–1558.
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in end-stage renal disease: Prevalence, associations and prognosis. Kidney Int. 1995;47:186–192.
   PubMed Web of Science ®Google Scholar
• London GM, Fabiani F. Left ventricular dysfunction in end-stage renal disease: Echocardiographic insights. In Parfrey PS, Harnett JD ( eds.). Cardiac dysfunction in chronic uremia. Boston: Kluwer; 1992:117–138.
   Google Scholar
• Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O. Left ventricular mass increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125–134.
   PubMed Web of Science ®Google Scholar
• Ha SK, Park HS, Kim SU, Park SH, Park CH, Lee HY, Han DS, Kim KW, Prevalence and patterns of left ventricular hypertrophy in patients with predialysis chronic renal failure. J Korean Med Sci. 1998;13:488–494.
   PubMedGoogle Scholar
• Straumann E, Bertel O, Meyer B, Weiss P, Misteli M, Blumberg A, Jenzer H. Symmetric and asymmetric left ventricular hypertrophy in patients with end-stage renal failure on long-term hemodialysis. Clin Cardiol. 1998;21:672–678.
   PubMedGoogle Scholar
• Greaves SC, Sharpe DN. Cardiovascular disease in patients with end-stage renal failure. Aust NZ J Med. 1992;22:153–158.
   PubMedGoogle Scholar
• Greaves C, Gamble GD, Collins JE, Whalley GA, Sharpe DN. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am J Kidney Dis. 1994;24:768–776.
   PubMed Web of Science ®Google Scholar
• Thuraisingham RC, Tucker B, Lipkin GW. Left ventricular hypertrophy in early renal failure. Nephrol Dial Transplant. 1994;7:859–860.
   Google Scholar
• London G, Parfrey PS. Cardiac disease in chronic uremia: Pathogenesis. Adv Renal Replace Ther. 1997;4:194–211.
   PubMedGoogle Scholar
• Levin A, Singer J, Thompson CR, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis. 1996;27:347–354.
   PubMed Web of Science ®Google Scholar
• Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol. 1986;57:450–458.
   PubMed Web of Science ®Google Scholar
• Cheriex EC, Leunissen KML, Janssen JHA, Mooy JMV, Van Hooff JP. Echocardiography of the inferior vena cava is a simple and reliable tool for estimation of dry weight in hemodialysis patients. Nephrol Dial Transplant. 1989;4:563–568.
   PubMed Web of Science ®Google Scholar
• De Simone G. Left ventricular geometry and hypotension in end-stage renal disease: A mechanical perspective. J Am Soc Nephrol. 2003;14:2421–2427.
   PubMedGoogle Scholar
• Devereux R, de Simone G, Ganau A Koren MJ, Mensah GA, Roman MJ. Left ventricular hypertrophy and hypertension. Clin Exper Hypertens. 1993;15:1025–1032.
   PubMed Web of Science ®Google Scholar
• Klingbeil A, Schmeider R. Not all left ventricular hypertrophy is created equal. Nephrol Dial Transplant. 1999;14:2803–2805.
   PubMed Web of Science ®Google Scholar
• Paoletti E, Cassottana P, Bellino D, Specchia C, Messa P, Cannella G. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis. 2002;40:728–736.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F, Tripepi G. CREED Investigators. Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients. J Hypertens. 1999;17:1751–1758.
   PubMed Web of Science ®Google Scholar
• Rao M, Pereira BJG. Optimal management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int. 2005;68:1432–1438.
   PubMed Web of Science ®Google Scholar
• London GM, Marchais SJ, Guérin AP, Fabiani F, Métivier F. Cardiovascular function in hemodialysis patients. Adv Nephrol. 1991;20:249–273.
   PubMedGoogle Scholar
• Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant. 1996;11:1277–1285.
   PubMed Web of Science ®Google Scholar
• Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int. 1995;47:884–890.
   PubMed Web of Science ®Google Scholar
• Lester LA, Sodt PC, Hutcheon N, Arcilla RA. Cardiac abnormalities in children with sickle cell anemia. Chest. 1990;98:1169–1174.
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Conte F, Marcelli D. The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity—the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant. 1998;13:1642–1644.
   PubMed Web of Science ®Google Scholar
• Low-Friedrich I, Grutzmacher P, Marz W, Bergmann M, Schoeppe W. Therapy with recombinant human erythropoietin reduces cardiac size and improves cardiac function in chronic hemodialysis patients. Am J Nephrol. 1991;11:54–60.
   PubMedGoogle Scholar
• Foley RN, Parfrey PS, Morgan J Barré PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325–1335.
   PubMed Web of Science ®Google Scholar
• London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol. 2001;12:2759–2767.
   PubMed Web of Science ®Google Scholar